Effects of Konjac Glucomannan on indicators of metabolic syndrome in adults with schizophrenia: A preliminary study

Sugeng Mashudi; Tukimin Bin Sansuwito; Teuku Nanda Saifullah Sulaiman; Dianita Rifqia Putri; Hariyatmi Hariyatmi

doi:10.53730/ijhs.v6n3.12873

Authors

Sugeng Mashudi
sugengmashudi@umpo.ac.id
Universitas Muhammadiyah Ponorogo, Ponorogo, Indonesia
Tukimin Bin Sansuwito Lincoln University College Malaysia, Kalana Jaya, Malaysia
Teuku Nanda Saifullah Sulaiman Universitas Gadjah Mada, Yogyakarta, Indonesia
Dianita Rifqia Putri Universitas Muhammadiyah Ponorogo, Ponorogo, Indonesia
Hariyatmi Universitas Muhammadiyah Surakarta, Surakarta, Indonesia

Keywords:

blood pressure, fasting blood glucose, health, konjac glucomannan, schizophrenia symptoms, triglycerides

Abstract

Objectives: effects of konjac glucomannan (KGM) in adults with schizophrenia. Method post feasibility trial with 20 participants with elevated blood glucose, blood pressure, and triglycerides. Intervention konjac glucomannan for 1 to 1.5 h, 1 tablet times every day for 4 weeks, and were encouraged to practise the exercises at home. Main Outcome Measures Indicators of blood pressure, fasting blood glucose, triglycerides, and schizophrenia symptoms. Results: There was high acceptability and good adherence. There were significant improvements in four indicators of metabolic syndrome including; Cholesterol (p,0.037), systolic (p,0.037) and diastolic blood pressure (p,0.869), as well as in GDP (p,0.004), schizophrenia symptoms (p,0.000). Conclusions: The program was feasible and acceptable, and participants' physiologic and physiological variables continued to improve. A larger controlled trial is now required to confirm these encouraging preliminary findings.

Downloads

Download data is not yet available.

References

Alothman, S., Alenazi, A. M., Alshehri, M. M., LeMaster, J., Thyfault, J., Rucker, J., & Kluding, P. M. (2021). Sedentary behavior counseling intervention in aging people with type 2 diabetes: a feasibility study. Clinical Medicine Insights: Endocrinology and Diabetes, 14, 11795514211040540.

Andrade, D. C., Flores-Opazo, M., Peñailillo, L., Delgado-Floody, P., Cano-Montoya, J., Vásquez-Gómez, J. A., & Alvarez, C. (2021). Similar adaptations to 10 weeks concurrent training on metabolic markers and physical performance in young, adult, and older adult women. Journal of Clinical Medicine, 10(23), 5582.

Beaudry, K. M., Surdi, J. C., Mari, A., & Devries, M. C. (2022). Exercise mode influences post‐exercise glucose sensitivity and insulin clearance in young, healthy males and females in a sex‐dependent manner: A randomized control trial. Physiological Reports, 10(13), e15354.

Behera, S. S., & Ray, R. C. (2016). Konjac glucomannan, un polisacárido prometedor de Amorphophallus konjac K. Koch en el cuidado de la salud. Revista Internacional de Macromoléculas Biológicas, 92, 942-956.

Bullard, T., Ji, M., An, R., Trinh, L., Mackenzie, M., & Mullen, S. P. (2019). A systematic review and meta-analysis of adherence to physical activity interventions among three chronic conditions: cancer, cardiovascular disease, and diabetes. BMC public health, 19(1), 1-11.

Cicero, A. F., Fogacci, F., Stoian, A. P., Vrablik, M., Al Rasadi, K., Banach, M., ... & Rizzo, M. (2021). Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels?. Current atherosclerosis reports, 23(10), 1-14.

Clifton, P. M. (2019). Diet, exercise and weight loss and dyslipidaemia. Pathology, 51(2), 222-226. https://doi.org/10.1016/j.pathol.2018.10.013

de Melo, I. S. V., Dos Santos, A. F., & Bueno, N. B. (2018). Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: systematic review and meta-analysis of randomized controlled trials. Pharmacological research, 128, 137-144. https://doi.org/10.1016/j.phrs.2017.09.010

Devaraj, R. D., Reddy, C. K., & Xu, B. (2019). Health-promoting effects of konjac glucomannan and its practical applications: A critical review. International journal of biological macromolecules, 126, 273-281. https://doi.org/10.1016/j.ijbiomac.2018.12.203

Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia research, 35, S93-S100. https://doi.org/10.1016/S0920-9964(98)00161-3

Dixon, L. (2017). What it will take to make coordinated specialty care available to anyone experiencing early schizophrenia: getting over the hump. JAMA psychiatry, 74(1), 7-8.

Djunaid, R., Sahar, J., Widyatuti, W., & Priyo, S. (2022). Predictive factors contributing to violent behavior in adolescents . International Journal of Health Sciences, 6(2), 1148–1159. https://doi.org/10.53730/ijhs.v6n2.11483

Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., ... & Rahimi, K. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet, 387(10022), 957-967. https://doi.org/10.1016/S0140-6736(15)01225-8

Frith, C. D., Blakemore, S. J., & Wolpert, D. M. (2000). Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Research Reviews, 31(2-3), 357-363. https://doi.org/10.1016/S0165-0173(99)00052-1

Ginsberg, H. N., Zhang, Y. L., & Hernandez-Ono, A. (2005). Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of medical research, 36(3), 232-240. https://doi.org/10.1016/j.arcmed.2005.01.005

He, H., Liu, Q., Li, N., Guo, L., Gao, F., Bai, L., ... & Lyu, J. (2020). Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiology and psychiatric sciences, 29.

Jiang, M., Li, H., Shi, J. S., & Xu, Z. H. (2018). Depolymerized konjac glucomannan: preparation and application in health care. Journal of Zhejiang University-Science B, 19(7), 505-514.

Kanaley, J. A., Colberg, S. R., Corcoran, M. H., Malin, S. K., Rodriguez, N. R., Crespo, C. J., ... & Zierath, J. R. (2022). Exercise/physical activity in individuals with type 2 diabetes: A consensus statement from the American College of Sports Medicine. Medicine and Science in Sports and Exercise.

Ma, R., Zhang, Y., Sun, Z., Xu, D., & Li, T. (2020). Effects of ambient particulate matter on fasting blood glucose: A systematic review and meta-analysis. Environmental pollution, 258, 113589. https://doi.org/10.1016/j.envpol.2019.113589

Mah, E., Chen, O., Liska, D. J., & Blumberg, J. B. (2022). Dietary Supplements for Weight Management: A Narrative Review of Safety and Metabolic Health Benefits. Nutrients, 14(9), 1787.

Malhotra, N., Grover, S., Chakrabarti, S., & Kulhara, P. (2013). Metabolic syndrome in schizophrenia. Indian journal of psychological medicine, 35(3), 227-240.

Mashudi, S., Putri, D., Aziz, Y. S., Larasati, S. F., Paramita M, S., & Widodo, S. P. (2022). Effects of konjac glucomannan on blood profile in schizophrenia with hyperglycemia. International Journal of Health Sciences, 6(S1), 714–720. https://doi.org/10.53730/ijhs.v6ns1.4820

Nie, Y., & Luo, F. (2021). Dietary fiber: an opportunity for a global control of hyperlipidemia. Oxidative Medicine and Cellular Longevity, 2021.

Onakpoya, I., Posadzki, P., & Ernst, E. (2014). The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Journal of the American College of Nutrition, 33(1), 70-78.

Saddichha, S., Ameen, S., & Akhtar, S. (2007). Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophrenia research, 95(1-3), 247-247.

Salawali, A. Q. ., Tahir, A. M. ., & Hardjo, M. . (2021). The effect of family education on the fulfillment of family health tasks in handling case of hypertension post earthquake in Sigi regency. International Journal of Health & Medical Sciences, 4(1), 136-140. https://doi.org/10.31295/ijhms.v4n1.1625

Schreurs, V., & Vancampfort, D. (2009). Metabolic syndrome in people with schizophrenia: a review. World Psychiatry: Official Journal of the World Psychiatric Association (WPA), 8(1), 15-22.

Sorić, T., Mavar, M., & Rumbak, I. (2021). Metabolic Syndrome and Dietary Habits in Hospitalized Patients with Schizophrenia: A Cross-Sectional Study. Medicina, 57(3), 255.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Vuksan, V., Sievenpiper, J. L., Xu, Z., Wong, E. Y., Jenkins, A. L., Beljan-Zdravkovic, U., ... & Stavro, M. P. (2001). Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. Journal of the American College of Nutrition, 20(sup5), 370S-380S.

Wang, C., Xu, M., Lv, W. P., Qiu, P., Gong, Y. Y., & Li, D. S. (2012). Study on rheological behavior of konjac glucomannan. Physics Procedia, 33, 25-30. https://doi.org/10.1016/j.phpro.2012.05.026

Wang, Y., Ning, Y., Yuan, C., Cui, B., Liu, G., & Zhang, Z. (2021). The protective mechanism of a debranched corn starch/konjac glucomannan composite against dyslipidemia and gut microbiota in high-fat-diet induced type 2 diabetes. Food & Function, 12(19), 9273-9285.

Warabi, Y., Kusdiana, D., & Saka, S. (2004). Reactivity of triglycerides and fatty acids of rapeseed oil in supercritical alcohols. Bioresource technology, 91(3), 283-287. https://doi.org/10.1016/S0960-8524(03)00202-5

Zhu, F. (2018). Modifications of konjac glucomannan for diverse applications. Food Chemistry, 256, 419-426. https://doi.org/10.1016/j.foodchem.2018.02.151